Key result
Biodegradable polymer biolimus-eluting stents did not significantly reduce the risk of major adverse cardiac events compared to durable polymer drug-eluting stents (RR 0.970), but significantly lowered the risk of very late stent thrombosis.
Why the study?
Does biodegradable polymer biolimus-eluting stents reduce major adverse cardiac events in patients undergoing percutaneous coronary interventions compared to durable polymer drug-eluting stents?
Meta-Analysis (n=11,015)
Does biodegradable polymer biolimus-eluting stents reduce major adverse cardiac events in patients undergoing percutaneous coronary interventions compared to durable polymer drug-eluting stents?
Relative Risk: 0.97 (95% CI 0.848–1.111)
p-value: p=0.662
Biodegradable polymer biolimus-eluting stents provide similar overall efficacy to durable polymer drug-eluting stents but may significantly reduce the risk of very late stent thrombosis.
No takes yet. Share an insight, caveat, or question.
No MACE reduction with biodegradable polymer biolimus-eluting stents; confirms lower very late stent thrombosis risk.
Ye et al. (2013) conducted a meta-analysis in Coronary artery disease requiring percutaneous coronary intervention (n=11,015). Biodegradable polymer biolimus-eluting stents vs. Durable polymer drug-eluting stents was evaluated on Major adverse cardiac events (MACE) (RR 0.970, 95% CI 0.848-1.111, p=0.662). Biodegradable polymer biolimus-eluting stents did not significantly reduce the risk of major adverse cardiac events compared to durable polymer drug-eluting stents (RR 0.970), but significantly lowered the risk of very late stent thrombosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: